Frontiers | Science News

Science News post list

Frontiers Communications

Frontiers Communications

Editor

1,331 news posts

Frontiers news

02 Mar 2021

2 March 2021 – Media statement

Article rejection: Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19. Dr. Frederick Fenter, Chief Executive Editor of Frontiers: “Regardless of the publication stage or subject of a manuscript, if the integrity of an article is called into question, our policy is to investigate. Upon further scrutiny by our Research Integrity team about the objectivity of this paper during the provisional acceptance phase, it was revealed that the article made a series of strong, unsupported claims based on studies with insufficient statistical significance, and at times, without the use of control groups. Further, the authors promoted their own specific ivermectin-based treatment which is inappropriate for a review article and against our editorial policies. “In our view, this paper does not offer an objective nor balanced scientific contribution to the evaluation of ivermectin as a potential treatment for COVID-19. Frontiers’ has published more than 2,000 rigorously peer-reviewed articles on COVID-19 since the pandemic erupted via our Coronavirus Knowledge Hub, and we are acutely aware of just how critical high-quality, objective research in this area is at this time. Frontiers takes no position on the efficacy of ivermectin as a treatment of patients with […]

Life sciences

05 Feb 2021

Chief Editor of Organic Chemistry is elected to the European Academy of Sciences

Professor Iwao Ojima We are proud to announce that Professor Iwao Ojima, Chief Editor of the Organic Chemistry section of  Frontiers in Chemistry has been recently elected to the European Academy of Sciences (EurASc) as a Fellow. Iwao Ojima is professor at the Department of Chemistry, College of Arts and Sciences, as well as the director of the Institute of Chemical Biology and Drug Discovery, Stony Brook University. He received his PhD from the University of Tokyo. Throughout his research career, Dr. Ojima has had numerous ties to the European scientific community – he was first recognized by European chemistry communities in organometallic chemistry, catalysis and fluorine chemistry, prior to joining the faculty at Stony Brook. His inventions on natural product-based anticancer agents were licensed to both French and Italian pharmaceutical companies. In addition, he served on the External Advisory Board of a highly innovative and successful multidisciplinary Center of Excellence, “Cell in Motion,” at the University of Münster and the Max Planck Institute for Molecular Biomedicine in Münster, Germany. He received numerous awards and honors, including 4 National Awards from the American Chemical Society in 4 different fields of chemistry, which is a very rare achievement. The European Academy of Sciences (EURASC) – the pan-European […]